loading
Schlusskurs vom Vortag:
$36.79
Offen:
$36.85
24-Stunden-Volumen:
1.31M
Relative Volume:
0.73
Marktkapitalisierung:
$7.82B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-10.30
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
-5.80%
1M Leistung:
-4.29%
6M Leistung:
-13.79%
1J Leistung:
-2.83%
1-Tages-Spanne:
Value
$36.71
$38.00
1-Wochen-Bereich:
Value
$36.61
$40.23
52-Wochen-Spanne:
Value
$29.17
$62.40

Revolution Medicines Inc Stock (RVMD) Company Profile

Name
Firmenname
Revolution Medicines Inc
Name
Telefon
415-766-3638
Name
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Name
Mitarbeiter
616
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
RVMD's Discussions on Twitter

Vergleichen Sie RVMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RVMD
Revolution Medicines Inc
37.76 7.82B 29.52M -567.06M -551.11M -3.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.31 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.34 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.14 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.31 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.39 28.51B 3.81B -644.79M -669.77M -6.24

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-16 Bestätigt Needham Buy
2024-07-12 Eingeleitet Barclays Overweight
2024-07-08 Eingeleitet Jefferies Buy
2024-04-12 Bestätigt Needham Buy
2024-04-10 Hochstufung Raymond James Outperform → Strong Buy
2024-03-11 Eingeleitet Piper Sandler Overweight
2024-01-05 Hochstufung BofA Securities Neutral → Buy
2024-01-04 Eingeleitet Wedbush Outperform
2023-11-16 Eingeleitet Raymond James Outperform
2023-02-28 Hochstufung JP Morgan Neutral → Overweight
2022-12-14 Eingeleitet Needham Buy
2022-10-21 Eingeleitet Oppenheimer Outperform
2022-05-20 Eingeleitet BofA Securities Neutral
2022-03-01 Hochstufung Stifel Hold → Buy
2021-09-23 Eingeleitet Stifel Hold
2021-08-12 Herabstufung Goldman Buy → Neutral
2021-05-18 Eingeleitet Goldman Buy
2020-05-21 Eingeleitet H.C. Wainwright Buy
2020-03-09 Eingeleitet Cowen Outperform
2020-03-09 Eingeleitet Guggenheim Buy
2020-03-09 Eingeleitet JP Morgan Neutral
Alle ansehen

Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten

pulisher
Jun 18, 2025

Revolution Medicines director Weber resigns ahead of annual meeting - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Revolution Medicines COO Horn sells $139k in stock - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Revolution Medicines COO Horn sells $139k in stock By Investing.com - Investing.com UK

Jun 18, 2025
pulisher
Jun 16, 2025

(RVMD) Proactive Strategies - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 04, 2025

(RVMD) Investment Analysis - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 27, 2025

rEvolution Appoints Brian Gabriel as Vice President of Marketing Communications - GlobeNewswire Inc.

May 27, 2025
pulisher
May 26, 2025

Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria

May 26, 2025
pulisher
May 24, 2025

(RVMD) On The My Stocks Page - news.stocktradersdaily.com

May 24, 2025
pulisher
May 15, 2025

First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Revolution Medicines begins phase 3 trial for lung cancer drug By Investing.com - Investing.com Canada

May 15, 2025
pulisher
May 15, 2025

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - BioSpace

May 15, 2025
pulisher
May 14, 2025

Revolution Medicines (RVMD) Receives Adjusted Price Target from - GuruFocus

May 14, 2025
pulisher
May 14, 2025

When (RVMD) Moves Investors should Listen - news.stocktradersdaily.com

May 14, 2025
pulisher
May 14, 2025

Revolution Medicines (RVMD) Initiates RASolve 301 Phase 3 Trial - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Revolution Medicines begins phase 3 trial for lung cancer drug - Investing.com

May 14, 2025
pulisher
May 14, 2025

Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Revolution Medicines (RVMD) Price Target Reduced by H.C. Wainwri - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright - TipRanks

May 14, 2025
pulisher
May 12, 2025

Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - Yahoo Finance

May 12, 2025
pulisher
May 10, 2025

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance

May 10, 2025
pulisher
May 09, 2025

Revolution’s KRAS drugs appear competitive in several lung cancer settings - Endpoints News

May 09, 2025
pulisher
May 08, 2025

Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs - TipRanks

May 08, 2025
pulisher
May 08, 2025

RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $8 - GuruFocus

May 08, 2025
pulisher
May 08, 2025

The Lustgarten Foundation Honors Revolution Medicines for Transformative Research in Pancreatic Cancer - PRWeb

May 08, 2025
pulisher
May 08, 2025

Oppenheimer Raises Price Target for RVMD, Maintains Outperform R - GuruFocus

May 08, 2025
pulisher
May 08, 2025

RVMD Price Target Lowered but Buy Rating Maintained by Guggenheim | RVMD Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Revolution Medicines (RVMD) Target Price Raised Amid Positive Ou - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Revolution Medicines (RVMD) Target Price Raised Amid Positive Outlook | RVMD Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Needham Reiterates Buy Rating for Revolution Medicines (RVMD) | RVMD Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Revolution Medicines Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Reven - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Revolution Medicines (RVMD) Advances Key Clinical Trials and Str - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update - Investing.com

May 07, 2025
pulisher
May 07, 2025

Revolution Medicines Q1 2025 Earnings Call Transcript - MarketBeat

May 07, 2025
pulisher
May 07, 2025

Revolution Medicines Q1 Net Loss Widens - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Revenue of $0.00 Million, Missing Estimates - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times

May 07, 2025
pulisher
May 05, 2025

Revolution Medicines patents new GTPase KRAS mutant inhibitors - BioWorld MedTech

May 05, 2025
pulisher
May 04, 2025

(RVMD) Investment Report - news.stocktradersdaily.com

May 04, 2025
pulisher
May 03, 2025

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN) - The Globe and Mail

May 03, 2025
pulisher
May 01, 2025

Revolution Medicines Inc [RVMD] Records 50-Day SMA of $37.82 - knoxdaily.com

May 01, 2025
pulisher
Apr 30, 2025

Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan

Apr 30, 2025
pulisher
Apr 30, 2025

Revolution Medicines, Inc. to Report Q1 2025 Financial Results on May 7, 2025 - Nasdaq

Apr 30, 2025
pulisher
Apr 30, 2025

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire

Apr 30, 2025
pulisher
Apr 29, 2025

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - AOL.com

Apr 29, 2025
pulisher
Apr 29, 2025

Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush - Defense World

Apr 29, 2025

Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.00
price up icon 1.52%
$36.00
price down icon 0.06%
$21.32
price down icon 0.15%
$99.07
price down icon 1.72%
$108.80
price up icon 2.21%
biotechnology ONC
$244.86
price up icon 1.07%
Kapitalisierung:     |  Volumen (24h):